Grabbing the Horns of a Dilemma: The Duration of Dual Antiplatelet Therapy After Stent
Despite the overwhelming success of percutaneous cardiac interventions, the interventional practitioner is commonly faced with a number of very simple questions to which the answers should be obvious but are in truth completely unknown. Perhaps the most common such question concerns the appropriate duration of dual antiplatelet therapy (the combination of aspirin and an inhibitor of platelet P2Y12) in patients who have received intracardiac stents. Most interventional cardiologists receive several such calls per week from patients and professional colleagues, and often have to spend a considerable amount of time negotiating antithrombotic drug treatment strategies in patients who need to undergo non-cardiac surgical procedures. (SELECT FULL TEXT TO CONTINUE)
- Received March 13, 2012.
- Accepted March 16, 2012.
- Copyright © 2012, American Heart Association, Inc. All rights reserved. Unauthorized use prohibited